Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ribavirin for Prevention of Hemorrhage in Dengue Fever
NCT06744777Phase 3Completed
- Sponsor
- Khyber Medical University
- Start
- Dec 2024
- Primary completion
- Apr 2025
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ribavirin in dengue fever (2 arms), sponsored by Khyber Medical University. Primary endpoint: Prevention of Clinically Significant Hemorrhage at 7 days. Started Dec 2024; status: completed.
02
Drugs
ribavirin
03
Conditions
dengue fever
Beyond the preview
Go deeper on NCT06744777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06744777.